Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease

Gut

Volumn 55, Issue 8, 2006, Pages 1104-1113

  Adachi, M ^a   Kurotani, R ^a   Morimura, K ^a   Shah, Y ^a   Sanford, M ^b   Madison, B B ^c   Gumucio, D L ^c   Marin, H E ^d   Peters, J M ^d   Young, H A ^b   Gonzalez, F J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; DOCUSATE SODIUM; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; VILLIN;

ANIMAL TISSUE; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DIARRHEA; ENTERITIS; EPITHELIUM CELL; FEMALE; GENE TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WEIGHT REDUCTION; WESTERN BLOTTING;

ANIMALS; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; DISEASE SUSCEPTIBILITY; EPITHELIAL CELLS; FEMALE; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LIGANDS; MICE; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION; PPAR GAMMA; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 33746159991     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.081745     Document Type: Article

References (55)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
2. Strober W, Fuss U, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549.
3. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33.
4. Mansen A, Guardiola-Diaz H, Rafter J, et al. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 1996;222:844-51.
5. Escher P, Braissant O, Basu-Modak S, et al. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001;142:4195-202.
6. Kliewer SA, Lenhard JM, Willson TM, et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995;83:813-19.
7. Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998;93:229-40.
8. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-61.
9. Kubota N, Terauchi Y, Miki H, et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999;4:597-609.
10. Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999;4:611-17.
11. Lazar MA. PPAR gamma, 10 years later. Biochimie 2005;87:9-13.
12. Gonzalez FJ. Getting fat: two new players in molecular adipogenesis. Cell Metab 2005;1:85-6.
13. Nicol CJ, Adachi M, Akiyama TE, et al. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens 2005;18:549-56.
14. Zhang H, Zhang A, Kohan DE, et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione- induced fluid retention. Proc Natl Acad Sci U S A 2005;102:9406-11.
15. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-6.
16. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002;2:748-59.
17. Girnun GD, Smith WM, Drori S, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A 2002;99:13771-6.
18. Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003;124:361-7.
19. Nicol CJ, Yoon M, Ward JM, et al. PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 2004;25:1747-55.
20. Sugie S, Vinh PQ, Rahman KM, et al. Suppressive effect of 1,4-phenylene diisothiocyanate on N-bulyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice. Int J Cancer 2005;117:524-30.
21. Lu J, Imamura K, Nomura S, et al. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res 2005;65:4769-74.
22. Yang K, Fan KM, Lamprecht SA, et al. Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc(1638 N/+) Mlh1(+/-) double mutant mice. Int J Cancer 2005;116:495-9.
23. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
24. Landi S, Moreno V, Gioia-Patricola L, et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003;63:3560-6.
25. Murtaugh MA, Ma KN, Caan BJ, et al. Interactions of peroxisome proliferator-activated receptor {gamma} and diet in etiology of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1224-9.
26. Drori S, Girnun GD, Tou L, et al. Hic-5 regulates an epithelial program mediated by PPARgamma. Genes Dev 2005;19:362-75.
27. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med 2005;201:1205-15.
28. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
29. Yang XY, Wang LH, Chen T, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000;275:4541-4.
30. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-9.
31. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001;193:827-38.
32. Nakajima A, Wada K, Miki H, et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 2001;120:460-9.
33. Saubermann LJ, Nakajima A, Wada K, et al. Peroxisome proliferator- activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 2002;8:330-9.
34. Dubuquoy L, Dharancy S, Nutten S, et al. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogostroenterological diseases. Lancet 2002;360:1410-18.
35. Kotayama K, Wada K, Nakajima A, et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003;124:1315-24.
36. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 2004;127:777-91.
37. Takagi T, Naito Y, Ichikawa H, et al. A PPAR-gamma ligand, 15-deoxy-Delta12,14-prostaglandin J(2), inhibited gastric mucosal injury induced by ischemia-reperfusion in rats. Redox Rep 2004;9:376-81.
38. Schaefer KL, Denevich S, Ma C, et al. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 2005;11:244-52.
39. Lytle C, Tod TJ, Vo KT, et al. The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis 2005;11:231-43.
40. Akiyama TE, Sakai S, Lambert G, et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 2002;22:2607-19.
41. Madison BB, Dunbar L, Qiao XT, et al. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem 2002;277:33275-83.
42. Axelsson LG, Landstrom E, Goldschmidt TJ, et al. Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+)-cell depleted, athymic and NK-cell depleted SCID mice. Inflamm Res 1996;45:181-91.
43. Wallace JL, Keenan CM, Gale D, et al. Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology 1992;102:18-27.
44. Kim K, Khaled AR, Reynolds D, et al. Characterization of an interleukin-7-dependent thymic cell line derived from a p53(-/-) mouse. J Immunol Methods 2003;274:177-84.
45. Akiyama TE, Baumann CT, Sakai S, et al. Selective intranuclear redistribution of PPAR isoforms by RXR alpha. Mol Endocrinol 2002;16:707-21.
46. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998;22:382-9.
47. Papadakis KA. Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep 2004;4:83-9.
48. Genolet R, Wahli W, Michalik L. PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets Inflamm Allergy 2004;3:361-75.
49. Lewis JD, Lichtenstein GR, Stein RB, et al. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001;96:3323-8.
50. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003;124:1265-76.
51. Welch JS, Ricote M, Akiyama TE, et al. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci USA 2003;100:6712-17.
52. Cui Y, Miyoshi K, Claudio E, et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 2002;277:17830-5.
53. Wagner KU, McAllister K, Ward T, et al. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 2001;10:545-53.
54. Wu GD. Is there a role for PPAR gamma in IBD? Yes, no, maybe. Gastroenterology 2003;124:1538-42.
55. Kim DJ, Bility MT, Billin AN, et al. PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ 2006;13:53-60.